Papers/PMID:28497060
Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
BioMed research international2017The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
(R)-carnitine — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The results of PP analysis showed that all-cause mortality in the L-C group was not lower than control (OR = 0.48, 95% CI: 0.21 to 1.06, P = 0.07, Figure 2(a)).”
Quoted verbatim from Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 1.5 to 6 g/day across included RCTs
- Population
- Adults with chronic heart failure in four RCTs reporting mortality; per-protocol analysis; L-carnitine versus placebo, routine or conventional treatment
Effect 0.48 odds ratio, 95% CI 0.21 to 1.06
Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials.2017PMID:28497060Permalink